SlideShare a Scribd company logo
1 of 36
Drugs Affecting the Urinary Tract 
and the Bladder 
Chapter 52 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Urinary Tract Infections (UTIs) 
• Second most common infection in the U.S. 
• More common in females 
• Patients with indwelling catheters or intermittent 
catherization are at risk 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Signs and Symptoms of a UTI 
• Urinary frequency 
• Urgency 
• Burning on urination (associated with cystitis) 
• Chills, fever, flank pain, and tenderness (associated with 
acute pyelonephritis) 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Treatment for UTIs 
• Antibiotics 
• Specific agents to sterilize the urinary tract 
• Drugs that: 
– Block spasms of the urinary tract muscles 
– Decrease urinary tract pain 
– Protect the cells of the bladder from irritation 
– Treat enlargement of the prostate gland in men 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Sites of Action of Drugs Acting on the 
Urinary Tract 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Anti-Infectives Used to Treat UTI 
• Cinoxacin (Cinobac): Interferes with DNA replication in 
gram-negative bacteria 
• Norfloxacin (Noroxin): Effective against even more gram-negative 
strains than is cinoxacin 
• Fosfomycin (Monurol): Has the convenience of only one 
dose 
• Nalidixic Acid (NegGram): Older drug, not effective 
against as many strains of gram-negative bacteria 
• Nitrofurantoin (Furadantin): Older drug with a very short 
half-life 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Anti-Infectives That Acidify the Urine 
• Methenamine (Hiprex) 
– Undergoes metabolism in the liver and is excreted in 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
urine 
– Has established dosage guidelines for children and 
comes in a suspension form 
• Methylene Blue (Urolene Blue) 
– Is widely distributed, metabolized in the tissues, and 
excreted in urine, bile, and feces
Anti-Infectives 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Actions 
– Act specifically within the urinary tract to destroy 
bacteria 
– They act either through direct antibiotic effect or 
through acidification 
• Indications 
– Chronic UTI 
– Adjunctive therapy in acute cystitis and 
pyelonephritis 
– Prophylaxis with urinary tract anatomical 
abnormalities and residual urine disorders
Anti-Infectives (cont.) 
• Pharmacokinetics 
– Vary with each drug 
• Contraindications 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
– Allergy 
• Caution 
– Renal dysfunction 
– Pregnancy and lactation
Anti-Infectives (cont.) 
• Adverse Effects 
– Nausea, vomiting, anorexia, bladder irritation, and 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
dysuria 
– Pruitus, urticaria, headache, dizziness, nervousness, 
and confusion 
• Drug-to-Drug Interactions 
– Vary with each agent
Question 
What type of drugs are used to treat UTIs? 
A. Broad spectrum antibiotics 
B. Those that protect the cells of the bladder from 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
irritation 
C. Quinine-based medications 
D. Beta blockers
Answer 
B. Protect the cells of the bladder from irritation 
Rationale: Drugs that: block spasms of the urinary tract 
muscles; decrease urinary tract pain; protect the cells of 
the bladder from irritation; treat enlargement of the 
prostate gland in men 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Urinary Tract Antispasmodics 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Actions 
– Block the spasms of urinary tract muscles 
– Blocking parasympathetic activity 
– Relaxing the detrusor and other urinary tract muscles 
• Indications 
– Bladder spasm and dysuria
Urinary Tract Antispasmodics (cont.) 
• Pharmacokinetics 
– Rapidly absorbed, widely distributes 
– Metabolized in the liver and excreted in the urine 
• Contraindications 
– Allergy 
– Pyloric or duodenal obstruction 
– Recent surgery 
– Obstructive urinary tract problems 
– Glaucoma, myasthenia gravis, or acute hemorrhage 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Urinary Tract Antispasmodics (cont.) 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Caution 
– Renal or hepatic dysfunction 
– Pregnancy and lactation 
• Adverse Effects 
– Related to blocking of the parasympathetic system 
• Drug-to-Drug Interactions 
– Phenothiazines 
– Haloperidol
Urinary Tract Analgesia 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Actions 
– When phenazopyridine is excreted in urine, it exerts 
a direct topical analgesic effect on the urinary 
mucosa 
• Indications 
– Relieve symptoms related to urinary tract irritation 
from infection, trauma, or surgery
Urinary Tract Analgesia (cont.) 
• Pharmacokinetics 
– Rapidly absorbed and has a very rapid onset of 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
action 
– Widely distributed 
– Metabolized in the liver and excreted in the urine 
• Contraindications 
– Allergy and renal dysfunction 
• Caution 
– Pregnancy and lactation
Urinary Tract Analgesia (cont.) 
• Adverse Effects 
– GI upset, headache, rash, reddish-orange coloring of 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
the urine 
– Renal and hepatic toxicity 
• Drug-to-Drug Interactions 
– Antibacterial agents
Bladder Protectants 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Actions 
– Heparin-like compound that has anticoagulant and 
fibrinolytic effects 
– Adheres to the bladder wall mucosal membranes and 
acts as a buffer to control cell permeability, 
preventing irritating solutes in the urine from 
reaching the bladder wall cells 
• Indications 
– Interstitial cystitis
Bladder Protectants (cont.) 
• Pharmacokinetics 
– Very little of the drug is absorbed 
– Metabolized in the liver and spleen, and excreted in 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
the urine 
• Contraindications 
– Condition that involve a risk of bleeding 
– Heparin induced thrombocytopenia
Bladder Protectants (cont.) 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Caution 
– Hepatic or splenic dysfunction 
– Pregnancy or lactation 
• Adverse Effects 
– Bleeding that may progress to hemorrhage 
– Headache, alopecia, GI disturbances 
• Drug-to-Drug Interactions 
– Anticoagulants, aspirin, or NSAIDs
Drugs for Treatment of Benign Prostatic 
Hyperplasia 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Actions 
– Varies with drug 
• Indications 
– Treats benign prostatic hypertrophy 
• Pharmacokinetics 
– Varies with drug 
• Contraindications 
– Allergy
Drugs for Treatment of Benign Prostatic 
Hyperplasia 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Cautions 
– Hepatic or renal dysfunction 
• Adverse Effects 
– Varies with drug 
– Headache, fatigue, dizziness, postural dizziness, 
lethargy, tachycardia, hypotension, GI upset 
– Decreased libido, impotence, and sexual dysfunction 
• Drug-to-Drug Interactions 
– Theophylline
Question 
Please answer the following question as true or false. 
An adverse effect of a bladder protectant is alopecia. 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Answer 
True 
Rationale: Adverse Effects: bleeding that may progress to 
hemorrhage; headache, alopecia, GI disturbances 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Use of Drugs Affecting the Urinary Tract 
Throughout the Lifespan 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Anti-Infectives 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Urinary Tract Antihistamines 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Drugs for Treatment of Benign 
Prostatic Hyperplasia 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Anti-Infectives 
• Assessment: History and Physical Exam 
• Nursing Diagnosis 
• Implementation 
• Evaluation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Urinary Tract 
Antispasmodics 
• Assessment: History and Physical Exam 
• Nursing Diagnosis 
• Implementation 
• Evaluation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Urinary Tract 
Analgesia 
• Assessment: History and Physical Exam 
• Nursing Diagnosis 
• Implementation 
• Evaluation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Bladder 
Protectants 
• Assessment: History and Physical Exam 
• Nursing Diagnosis 
• Implementation 
• Evaluation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Drugs for 
Treatment of Benign Prostatic Hyperplasia 
• Assessment: History and Physical Exam 
• Nursing Diagnosis 
• Implementation 
• Evaluation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Question 
What is an appropriate nursing diagnoses for a patient 
taking a urinary anti-infective? 
A. Disturbed sensory perception (kinesthetic, tactile, 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
visual) 
B. Incontinence 
C. Chronic pain 
D. Discolored urine
Answer 
A. Disturbed sensory perception (kinesthetic, tactile, 
visual) 
Rationale: Nursing diagnoses related to drug therapy might 
include: acute pain related to GI, CNS, or skin effects of 
drug; disturbed sensory perception (kinesthetic, tactile, 
visual) related to CNS effects; impaired urinary 
elimination related to underlying problem necessitating 
drug therapy; risk for injury related to possible CNS 
effects; deficient knowledge regarding drug therapy 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

More Related Content

What's hot

Ppt chapter 42
Ppt chapter 42Ppt chapter 42
Ppt chapter 42stanbridge
 
Ppt chapter 37-1
Ppt chapter 37-1Ppt chapter 37-1
Ppt chapter 37-1stanbridge
 
Ppt chapter 50-1
Ppt chapter 50-1Ppt chapter 50-1
Ppt chapter 50-1stanbridge
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1stanbridge
 
Ppt chapter 20-1
Ppt chapter 20-1Ppt chapter 20-1
Ppt chapter 20-1stanbridge
 
Ppt chapter 40
Ppt chapter 40Ppt chapter 40
Ppt chapter 40stanbridge
 
Ppt chapter 33
Ppt chapter 33Ppt chapter 33
Ppt chapter 33stanbridge
 
Ppt chapter 32-1
Ppt chapter 32-1Ppt chapter 32-1
Ppt chapter 32-1stanbridge
 
Ppt chapter 35
Ppt chapter 35Ppt chapter 35
Ppt chapter 35stanbridge
 
Ppt chapter 02
Ppt chapter 02Ppt chapter 02
Ppt chapter 02stanbridge
 
Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59stanbridge
 
Ppt chapter 51-1
Ppt chapter 51-1Ppt chapter 51-1
Ppt chapter 51-1stanbridge
 
Ppt chapter 30-1
Ppt chapter 30-1Ppt chapter 30-1
Ppt chapter 30-1stanbridge
 
Ppt chapter 37
Ppt chapter 37Ppt chapter 37
Ppt chapter 37stanbridge
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16stanbridge
 
Diuretics & Antidiuretics (Pharmacology)
Diuretics &  Antidiuretics (Pharmacology)Diuretics &  Antidiuretics (Pharmacology)
Diuretics & Antidiuretics (Pharmacology)sarthak845950
 
Ppt chapter 36-1
Ppt chapter 36-1Ppt chapter 36-1
Ppt chapter 36-1stanbridge
 
Reproductive System Drugs
Reproductive System DrugsReproductive System Drugs
Reproductive System DrugsTosca Torres
 
Ppt chapter 13
Ppt chapter 13Ppt chapter 13
Ppt chapter 13stanbridge
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36stanbridge
 

What's hot (20)

Ppt chapter 42
Ppt chapter 42Ppt chapter 42
Ppt chapter 42
 
Ppt chapter 37-1
Ppt chapter 37-1Ppt chapter 37-1
Ppt chapter 37-1
 
Ppt chapter 50-1
Ppt chapter 50-1Ppt chapter 50-1
Ppt chapter 50-1
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1
 
Ppt chapter 20-1
Ppt chapter 20-1Ppt chapter 20-1
Ppt chapter 20-1
 
Ppt chapter 40
Ppt chapter 40Ppt chapter 40
Ppt chapter 40
 
Ppt chapter 33
Ppt chapter 33Ppt chapter 33
Ppt chapter 33
 
Ppt chapter 32-1
Ppt chapter 32-1Ppt chapter 32-1
Ppt chapter 32-1
 
Ppt chapter 35
Ppt chapter 35Ppt chapter 35
Ppt chapter 35
 
Ppt chapter 02
Ppt chapter 02Ppt chapter 02
Ppt chapter 02
 
Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59
 
Ppt chapter 51-1
Ppt chapter 51-1Ppt chapter 51-1
Ppt chapter 51-1
 
Ppt chapter 30-1
Ppt chapter 30-1Ppt chapter 30-1
Ppt chapter 30-1
 
Ppt chapter 37
Ppt chapter 37Ppt chapter 37
Ppt chapter 37
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16
 
Diuretics & Antidiuretics (Pharmacology)
Diuretics &  Antidiuretics (Pharmacology)Diuretics &  Antidiuretics (Pharmacology)
Diuretics & Antidiuretics (Pharmacology)
 
Ppt chapter 36-1
Ppt chapter 36-1Ppt chapter 36-1
Ppt chapter 36-1
 
Reproductive System Drugs
Reproductive System DrugsReproductive System Drugs
Reproductive System Drugs
 
Ppt chapter 13
Ppt chapter 13Ppt chapter 13
Ppt chapter 13
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36
 

Viewers also liked

Viewers also liked (8)

INTRODUCTION TO THE ORGANOLEPTIC TASTING Of Olive Oil
INTRODUCTION TO THE ORGANOLEPTIC TASTING Of Olive Oil INTRODUCTION TO THE ORGANOLEPTIC TASTING Of Olive Oil
INTRODUCTION TO THE ORGANOLEPTIC TASTING Of Olive Oil
 
Greece
GreeceGreece
Greece
 
Anti infective
Anti infectiveAnti infective
Anti infective
 
Urinary tract infections 2
Urinary tract infections 2Urinary tract infections 2
Urinary tract infections 2
 
Ppt chapter 24
Ppt chapter 24Ppt chapter 24
Ppt chapter 24
 
Ppt chapter 30
Ppt chapter 30Ppt chapter 30
Ppt chapter 30
 
Anticholinergics
AnticholinergicsAnticholinergics
Anticholinergics
 
Urine Interpretation / Test / Analysis
Urine Interpretation / Test / AnalysisUrine Interpretation / Test / Analysis
Urine Interpretation / Test / Analysis
 

Similar to Ppt chapter 52-1

Similar to Ppt chapter 52-1 (20)

Ppt chapter 52
Ppt chapter 52Ppt chapter 52
Ppt chapter 52
 
Ppt chapter 58
Ppt chapter 58Ppt chapter 58
Ppt chapter 58
 
Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59
 
Ppt chapter 57
Ppt chapter 57Ppt chapter 57
Ppt chapter 57
 
Ppt chapter 26-1
Ppt chapter 26-1Ppt chapter 26-1
Ppt chapter 26-1
 
Ppt chapter 58
Ppt chapter 58Ppt chapter 58
Ppt chapter 58
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48
 
Ppt chapter 42
Ppt chapter 42Ppt chapter 42
Ppt chapter 42
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1
 
ASSESSMENT OF RENAL AND URINARY TRACT INFECTION
ASSESSMENT OF RENAL AND URINARY TRACT INFECTIONASSESSMENT OF RENAL AND URINARY TRACT INFECTION
ASSESSMENT OF RENAL AND URINARY TRACT INFECTION
 
Ppt chapter 51
Ppt chapter 51Ppt chapter 51
Ppt chapter 51
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36
 
Ppt chapter 56
Ppt chapter 56Ppt chapter 56
Ppt chapter 56
 
Ppt chapter 38-1
Ppt chapter 38-1Ppt chapter 38-1
Ppt chapter 38-1
 
Ppt chapter 56
Ppt chapter 56Ppt chapter 56
Ppt chapter 56
 
Ppt chapter 46
Ppt chapter 46Ppt chapter 46
Ppt chapter 46
 
Ppt chapter 37
Ppt chapter 37Ppt chapter 37
Ppt chapter 37
 

More from stanbridge

Micro Lab 3 Lecture
Micro Lab 3 LectureMicro Lab 3 Lecture
Micro Lab 3 Lecturestanbridge
 
Creating a poster v2
Creating a poster v2Creating a poster v2
Creating a poster v2stanbridge
 
Creating a poster
Creating a posterCreating a poster
Creating a posterstanbridge
 
OT 5018 Thesis Dissemination
OT 5018 Thesis DisseminationOT 5018 Thesis Dissemination
OT 5018 Thesis Disseminationstanbridge
 
Ot5101 005 week 5
Ot5101 005 week 5Ot5101 005 week 5
Ot5101 005 week 5stanbridge
 
Ot5101 005 week4
Ot5101 005 week4Ot5101 005 week4
Ot5101 005 week4stanbridge
 
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors stanbridge
 
Ch 5 developmental stages of the learner
Ch 5   developmental stages of the learnerCh 5   developmental stages of the learner
Ch 5 developmental stages of the learnerstanbridge
 
OT 5101 week2 theory policy
OT 5101 week2 theory policyOT 5101 week2 theory policy
OT 5101 week2 theory policystanbridge
 
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentOT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentstanbridge
 
NUR 304 Chapter005
NUR 304 Chapter005NUR 304 Chapter005
NUR 304 Chapter005stanbridge
 
NUR 3043 Chapter007
NUR 3043 Chapter007NUR 3043 Chapter007
NUR 3043 Chapter007stanbridge
 
NUR 3043 Chapter006
NUR 3043 Chapter006NUR 3043 Chapter006
NUR 3043 Chapter006stanbridge
 
NUR 3043 Chapter004
NUR 3043 Chapter004NUR 3043 Chapter004
NUR 3043 Chapter004stanbridge
 
3043 Chapter009
3043 Chapter0093043 Chapter009
3043 Chapter009stanbridge
 
3043 Chapter008
 3043 Chapter008 3043 Chapter008
3043 Chapter008stanbridge
 
Melnyk ppt chapter_21
Melnyk ppt chapter_21Melnyk ppt chapter_21
Melnyk ppt chapter_21stanbridge
 
Melnyk ppt chapter_22
Melnyk ppt chapter_22Melnyk ppt chapter_22
Melnyk ppt chapter_22stanbridge
 

More from stanbridge (20)

Micro Lab 3 Lecture
Micro Lab 3 LectureMicro Lab 3 Lecture
Micro Lab 3 Lecture
 
Creating a poster v2
Creating a poster v2Creating a poster v2
Creating a poster v2
 
Creating a poster
Creating a posterCreating a poster
Creating a poster
 
Sample poster
Sample posterSample poster
Sample poster
 
OT 5018 Thesis Dissemination
OT 5018 Thesis DisseminationOT 5018 Thesis Dissemination
OT 5018 Thesis Dissemination
 
Ot5101 005 week 5
Ot5101 005 week 5Ot5101 005 week 5
Ot5101 005 week 5
 
Ot5101 005 week4
Ot5101 005 week4Ot5101 005 week4
Ot5101 005 week4
 
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors
 
Ch 5 developmental stages of the learner
Ch 5   developmental stages of the learnerCh 5   developmental stages of the learner
Ch 5 developmental stages of the learner
 
OT 5101 week2 theory policy
OT 5101 week2 theory policyOT 5101 week2 theory policy
OT 5101 week2 theory policy
 
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentOT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessment
 
Ot5101 week1
Ot5101 week1Ot5101 week1
Ot5101 week1
 
NUR 304 Chapter005
NUR 304 Chapter005NUR 304 Chapter005
NUR 304 Chapter005
 
NUR 3043 Chapter007
NUR 3043 Chapter007NUR 3043 Chapter007
NUR 3043 Chapter007
 
NUR 3043 Chapter006
NUR 3043 Chapter006NUR 3043 Chapter006
NUR 3043 Chapter006
 
NUR 3043 Chapter004
NUR 3043 Chapter004NUR 3043 Chapter004
NUR 3043 Chapter004
 
3043 Chapter009
3043 Chapter0093043 Chapter009
3043 Chapter009
 
3043 Chapter008
 3043 Chapter008 3043 Chapter008
3043 Chapter008
 
Melnyk ppt chapter_21
Melnyk ppt chapter_21Melnyk ppt chapter_21
Melnyk ppt chapter_21
 
Melnyk ppt chapter_22
Melnyk ppt chapter_22Melnyk ppt chapter_22
Melnyk ppt chapter_22
 

Ppt chapter 52-1

  • 1. Drugs Affecting the Urinary Tract and the Bladder Chapter 52 Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 2. Urinary Tract Infections (UTIs) • Second most common infection in the U.S. • More common in females • Patients with indwelling catheters or intermittent catherization are at risk Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 3. Signs and Symptoms of a UTI • Urinary frequency • Urgency • Burning on urination (associated with cystitis) • Chills, fever, flank pain, and tenderness (associated with acute pyelonephritis) Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 4. Treatment for UTIs • Antibiotics • Specific agents to sterilize the urinary tract • Drugs that: – Block spasms of the urinary tract muscles – Decrease urinary tract pain – Protect the cells of the bladder from irritation – Treat enlargement of the prostate gland in men Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 5. Sites of Action of Drugs Acting on the Urinary Tract Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 6. Anti-Infectives Used to Treat UTI • Cinoxacin (Cinobac): Interferes with DNA replication in gram-negative bacteria • Norfloxacin (Noroxin): Effective against even more gram-negative strains than is cinoxacin • Fosfomycin (Monurol): Has the convenience of only one dose • Nalidixic Acid (NegGram): Older drug, not effective against as many strains of gram-negative bacteria • Nitrofurantoin (Furadantin): Older drug with a very short half-life Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 7. Anti-Infectives That Acidify the Urine • Methenamine (Hiprex) – Undergoes metabolism in the liver and is excreted in Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins urine – Has established dosage guidelines for children and comes in a suspension form • Methylene Blue (Urolene Blue) – Is widely distributed, metabolized in the tissues, and excreted in urine, bile, and feces
  • 8. Anti-Infectives Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Actions – Act specifically within the urinary tract to destroy bacteria – They act either through direct antibiotic effect or through acidification • Indications – Chronic UTI – Adjunctive therapy in acute cystitis and pyelonephritis – Prophylaxis with urinary tract anatomical abnormalities and residual urine disorders
  • 9. Anti-Infectives (cont.) • Pharmacokinetics – Vary with each drug • Contraindications Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins – Allergy • Caution – Renal dysfunction – Pregnancy and lactation
  • 10. Anti-Infectives (cont.) • Adverse Effects – Nausea, vomiting, anorexia, bladder irritation, and Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins dysuria – Pruitus, urticaria, headache, dizziness, nervousness, and confusion • Drug-to-Drug Interactions – Vary with each agent
  • 11. Question What type of drugs are used to treat UTIs? A. Broad spectrum antibiotics B. Those that protect the cells of the bladder from Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins irritation C. Quinine-based medications D. Beta blockers
  • 12. Answer B. Protect the cells of the bladder from irritation Rationale: Drugs that: block spasms of the urinary tract muscles; decrease urinary tract pain; protect the cells of the bladder from irritation; treat enlargement of the prostate gland in men Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 13. Urinary Tract Antispasmodics Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Actions – Block the spasms of urinary tract muscles – Blocking parasympathetic activity – Relaxing the detrusor and other urinary tract muscles • Indications – Bladder spasm and dysuria
  • 14. Urinary Tract Antispasmodics (cont.) • Pharmacokinetics – Rapidly absorbed, widely distributes – Metabolized in the liver and excreted in the urine • Contraindications – Allergy – Pyloric or duodenal obstruction – Recent surgery – Obstructive urinary tract problems – Glaucoma, myasthenia gravis, or acute hemorrhage Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 15. Urinary Tract Antispasmodics (cont.) Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Caution – Renal or hepatic dysfunction – Pregnancy and lactation • Adverse Effects – Related to blocking of the parasympathetic system • Drug-to-Drug Interactions – Phenothiazines – Haloperidol
  • 16. Urinary Tract Analgesia Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Actions – When phenazopyridine is excreted in urine, it exerts a direct topical analgesic effect on the urinary mucosa • Indications – Relieve symptoms related to urinary tract irritation from infection, trauma, or surgery
  • 17. Urinary Tract Analgesia (cont.) • Pharmacokinetics – Rapidly absorbed and has a very rapid onset of Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins action – Widely distributed – Metabolized in the liver and excreted in the urine • Contraindications – Allergy and renal dysfunction • Caution – Pregnancy and lactation
  • 18. Urinary Tract Analgesia (cont.) • Adverse Effects – GI upset, headache, rash, reddish-orange coloring of Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins the urine – Renal and hepatic toxicity • Drug-to-Drug Interactions – Antibacterial agents
  • 19. Bladder Protectants Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Actions – Heparin-like compound that has anticoagulant and fibrinolytic effects – Adheres to the bladder wall mucosal membranes and acts as a buffer to control cell permeability, preventing irritating solutes in the urine from reaching the bladder wall cells • Indications – Interstitial cystitis
  • 20. Bladder Protectants (cont.) • Pharmacokinetics – Very little of the drug is absorbed – Metabolized in the liver and spleen, and excreted in Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins the urine • Contraindications – Condition that involve a risk of bleeding – Heparin induced thrombocytopenia
  • 21. Bladder Protectants (cont.) Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Caution – Hepatic or splenic dysfunction – Pregnancy or lactation • Adverse Effects – Bleeding that may progress to hemorrhage – Headache, alopecia, GI disturbances • Drug-to-Drug Interactions – Anticoagulants, aspirin, or NSAIDs
  • 22. Drugs for Treatment of Benign Prostatic Hyperplasia Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Actions – Varies with drug • Indications – Treats benign prostatic hypertrophy • Pharmacokinetics – Varies with drug • Contraindications – Allergy
  • 23. Drugs for Treatment of Benign Prostatic Hyperplasia Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Cautions – Hepatic or renal dysfunction • Adverse Effects – Varies with drug – Headache, fatigue, dizziness, postural dizziness, lethargy, tachycardia, hypotension, GI upset – Decreased libido, impotence, and sexual dysfunction • Drug-to-Drug Interactions – Theophylline
  • 24. Question Please answer the following question as true or false. An adverse effect of a bladder protectant is alopecia. Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 25. Answer True Rationale: Adverse Effects: bleeding that may progress to hemorrhage; headache, alopecia, GI disturbances Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 26. Use of Drugs Affecting the Urinary Tract Throughout the Lifespan Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 27. Prototype Anti-Infectives Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 28. Prototype Urinary Tract Antihistamines Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 29. Prototype Drugs for Treatment of Benign Prostatic Hyperplasia Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 30. Nursing Considerations for Anti-Infectives • Assessment: History and Physical Exam • Nursing Diagnosis • Implementation • Evaluation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 31. Nursing Considerations for Urinary Tract Antispasmodics • Assessment: History and Physical Exam • Nursing Diagnosis • Implementation • Evaluation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 32. Nursing Considerations for Urinary Tract Analgesia • Assessment: History and Physical Exam • Nursing Diagnosis • Implementation • Evaluation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 33. Nursing Considerations for Bladder Protectants • Assessment: History and Physical Exam • Nursing Diagnosis • Implementation • Evaluation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 34. Nursing Considerations for Drugs for Treatment of Benign Prostatic Hyperplasia • Assessment: History and Physical Exam • Nursing Diagnosis • Implementation • Evaluation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 35. Question What is an appropriate nursing diagnoses for a patient taking a urinary anti-infective? A. Disturbed sensory perception (kinesthetic, tactile, Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins visual) B. Incontinence C. Chronic pain D. Discolored urine
  • 36. Answer A. Disturbed sensory perception (kinesthetic, tactile, visual) Rationale: Nursing diagnoses related to drug therapy might include: acute pain related to GI, CNS, or skin effects of drug; disturbed sensory perception (kinesthetic, tactile, visual) related to CNS effects; impaired urinary elimination related to underlying problem necessitating drug therapy; risk for injury related to possible CNS effects; deficient knowledge regarding drug therapy Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins